Kenneth J. O’Byrne

机构：Princess Alexandra Hospital · ORCID：0000-0002-6754-5633

发表论文 1158 篇 · 总被引 47818 次 · h-index 91

代表论文

• Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer (2025 · Nature Medicine · 被引 39)
• Frontline sigvotatug vedotin plus pembrolizumab vs pembrolizumab for non-small cell lung cancer with PD-L1 tumor proportion score ≥50%: phase III study design (2025 · Future Oncology · 被引 5)
• A phase I study of the OX40 agonist BGB-A445 with or without tislelizumab, an anti–PD-1 monoclonal antibody, in patients with advanced solid tumors: dose-escalation results (2025 · Cancer Chemotherapy and Pharmacology · 被引 4)
• Treatment-Free Survival Over 6 Years of Follow-up in Patients With Metastatic NSCLC Treated With First-Line Nivolumab Plus Ipilimumab Versus Chemotherapy in CheckMate 227 Part 1 (2025 · Journal of Thoracic Oncology · 被引 4)
• Impact of PD-L1 on first-line osimertinib outcomes in EGFR-mutant NSCLC: real-world data from the AURORA25 study and meta-analysis (2025 · Lung Cancer · 被引 3)
• The inner nuclear membrane protein, Banf1, has an essential role in triple negative breast cancer cell proliferation and survival (2025 · Scientific Reports · 被引 2)